Why does Organs-on-Chips adoption take time?

Extracted from the Organs-On-Chips Market and Technology Landscape report, Yole Développement, 2019


  • Market growth is pushing changes in materials and technologies.
  • OOC: a rapid pace for a high-potential market.
  • Too many expectations, too much hype?
  • OOC is a multidisciplinary field, and various parameters will shape tomorrow's technology.


LYON, France – October 29, 2019: This year, in its latest Organs-On-Chips Market and Technology Landscape report, Yole Développement (Yole) announces an OOC market multiplied by 4 between 2016 and 2018, reaching US$29.6 million in 2018. This market is evolving surely but slowly in the right way even if the adoption of OOC technologies takes time. Yole’s analysts highlight the high potential of today’s solutions but also point out in their report, the need to adapt the current technologies to the demand coming from the industry.
“Numerous emerging companies have appeared over the past two years in the OOC competitive landscape to propose innovative technologies”, says Marjorie Villien, PhD. Technology & Market Analyst at Yole. “Today this industry is growing nicely with lot of new players and ingenious solutions. However we still see an important gap between current technologies and market needs. Our report analyzes the status of this industry and highlights what organ-on-chip developers need to do to propose relevant products in the future.”
The market research & strategy consulting company, Yole is offering today a snapshot of the OOC industry with key figures and technology trends.

OOC has the potential to enable better predictive, physiologically-relevant in-vitro drug testing. This could save hundreds of millions of dollars in development costs, reduce drug development time, and avoid failures due to lack of predictiveness from alternative models like 2D cell cultures and animals.
“Many new players are entering this market with new organ models, and most players that were present two years ago have made noticeable progress”, asserts Sebastien Clerc, Technology & Market Analyst at Yole. “Top players like Mimetas and TissUse now have recurring sales and a consistent revenue stream, and many players are leveraging their OOC devices to provide testing services to their partners in the pharmaceutical, cosmetics, and consumer goods industries – for testing the efficacy and safety of new drugs and products.”

Organs-on-chips can take various shapes and appearances, depending on their purpose. The drug development process is long and complex, and needs are not the same at the early drug-screening stages as they are in the late preclinical trial stages.
In this context, some players are more specialized in plate formats for automation and high throughput, while others prefer developing single independent chips. Some players develop key solutions based on single organ models, while others propose multi-organ models to assess metabolic interactions between organs. Every technology is different and has specific application domains.
On the materials side, important changes are happening, announces Yole in the OOC report.
Two years ago, Yole’s analysts were concerned about the ability of OOC companies to switch from PDMS devices in order to scale-up production. Today, it appears that most companies have successfully managed this transition, or at least engaged with the right partners early enough to avoid the problems young companies usually face at this stage.
“At the moment, polymer is the preferred material, but some companies use glass,” says Sébastien Clerc from Yole. “Some companies pursue the development of new soft materials to keep the interesting properties of PDMS (stretchability, porosity) while eliminating its drawbacks. The next step could be the integration of more silicon pieces”.
Indeed, sensing directly at the cell level is a necessity, but right now only a few companies are moving in this direction. This is why silicon is not commonly used in OOC. Yole’s analysts expect this to change by 2024…
In its new report, Organs-On-Chips Market and Technology Landscape, in addition to the major trends and evolutions of the industry, feedback from end-users, evolution of business models and more, Yole details the evolution of the materials mix, along with various other technical aspects such as the added-value of flow control and vascularization of organs, the emergence of new materials combining the preferred properties of several existing ones, the importance of cell sources, and more. A detailed description of this report is available on

Yole’s Photonics & Sensing team presents key results all year long, during key trade shows and conferences. In this context, analysts propose an Organs-on-Chips presentation next month in Tokyo:
“Overview of Promising Applications of Microfluidic Technologies: Organs-on-Chips, Sequencing, and Biotechnologies” on November 15, at 12:30 PM – Microfluidics & Organ-on-a-Chip Asia (Tokyo, Japan – Nov. 14&15, 2019).
Speaker: Sébastien Clerc Technology & Market Analyst | Microfluidics & Medical Technologies, Life Sciences & Healthcare Division at Yole Développement
In addition, the team will be at COMPAMED 2019 to meet the leading companies and share its vision of the industry.
Make sure to meet Yole’s experts and get a deep understanding of the markets evolution.

Stay tuned on to download Yole’s presentations!

OOC : Organs-on-Chips
PDMS : Polydimethylsiloxane

Connect with us

About the report:

Newsletter subscription

About Yole Développement